Laboratory evaluation of clopidogrel responsiveness by platelet function and genetic methods.
Am J Hematol
; 86(12): 1032-4, 2011 Dec.
Article
em En
| MEDLINE
| ID: mdl-21812020
ABSTRACT
Clopidogrel is a widely used antiplatelet agent that irreversibly inhibits platelet P2Y12 ADP receptors after conversion to an active metabolite. There are a number of laboratory tests capable of detecting clopidogrel-induced platelet inhibition and published literature correlates suboptimal clopidogrel response to adverse cardiovascular outcomes. Genetic polymorphisms are thought to affect conversion of the prodrug to the active metabolite, and the FDA has recently added a black-box warning to clopidogrel to highlight the effects of these polymorphisms on drug bioavailability and to inform prescribers about the availability of genetic testing. For these reasons, there is growing interest in the use of laboratory tests to monitor patients treated with clopidogrel. This article summarizes the currently available laboratory testing, including platelet function tests and genotyping for CYP2C19 variants.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Plaquetas
/
Ticlopidina
/
Inibidores da Agregação Plaquetária
/
Monitoramento de Medicamentos
Limite:
Humans
Idioma:
En
Ano de publicação:
2011
Tipo de documento:
Article